ASCO Week in Review- Rayno Biopharmaceutical Stocks
The market action over the past week focused on speculative stocks rather than the overall biopharmaceutical sector. Major ETFs over five days were mixed with the smaller cap XBI up over 1%, the IBB flat and the FBT trailed down 0.7%. Many of the oncology stocks with anticipated clinical news were up prior to ASCO. The S&P Healthcare sector was down 0.87% for the week.The biotech sector overall had a great May but is now fighting a “triple top”. See our previous ASCO 2015 Reviews.
Rayno Small Caps were the big winners for the week: Fibrocell Sciences (FCSC) up 22.3% to $5.65 and Ignyta (RXDX) up 85.8% to $18.49.
Celldex Therapeutics (CLDX) was up 8.36% for the month of May but sold off down 7.66% for the week.
Rayno Large Caps-Gilead Science (GILD) hovered up 1.55% and Regeneron (REGN) up 5.2% on anticipated good news from a FDA review of its cholesterol lowering drug next Tuesday. Cholesterol Drug- Regeneron
Rayno Mid Caps- Clovis Oncology (CLVS) was down 7% for the week to $86 after hitting $100 earlier in the month. Seattle Genetics (SGEN) was up 8.77%,
Many biotech stocks barely rallied through ASCO week but CAR-T plays regained momentum due to buyout rumors and deals:
Cellectis (CLS) up 1.3%, JUNO up 29.9%, KITE Pharma (KITE) up 12.77%, Ziopharma (ZIOP) up 4.43%.
Agios Pharmaceuticals (AGIO) is focused in cancer metabolism and rare genetic disorders with two pipeline products. AGIO is one of the hottest stocks of the past 12 months bounced off April lows and was up 27.55% over the past month but flat for the week.
Four solid “mid-cap” stocks in the $10-30B market cap range should be on your watch list in the months ahead for deals and product news: Alnylam (ALNY), Biomarin (BMRN), Incyte (INCY) and Vertex (VRTX). Only Vertex Pharmaceuticals has been on our focus list. All are trading near 52 week highs and are mentioned in M&A talk.
Biotech Triple Top